Abstract
Histone deacetylase inhibitors have progressed rapidly from the laboratory to clinical testing. This review highlights the promising data for their combination with a wide range of established and novel anticancer agents and discusses the mechanisms that underpin these interactions.
| Original language | English |
|---|---|
| Pages (from-to) | 689-694 |
| Number of pages | 6 |
| Journal | British Journal of Cancer |
| Volume | 99 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2 Sept 2008 |